|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
Ƥ������ |
| ��������������� | |
|
�ŷ� |
|
���� |
|
��Ȩ |
|
����Ȫ |
|
������ |
| PubMed | |
|
Article by Zhang,f |
|
Article by Diao,t |
|
Article by Luo,q |
|
Article by Zhang,S.Q |
|
Article by Zhang,T.B |
��������Ƥ����
�ŷ�1,2,����3,��Ȩ1,����Ȫ4,������1
1. ������Ƥ����������
2. ʮ����̫��ҽԺ
3. ����ҽ�ƴ�ѧ��������Ƥ����������
4. ������Ƥ����������Ƥ����
��ժҪ�� �������ǽ��ʰ�Ĥ����Ҫ��ɳɷ֣��Ա�Ƥ�����Ϲ�������Ҫ���á��û���ı������ܶ��ת¼����֮�临�ӵ�����ù�ͬ���ء���������ͻ��ɵ��¶�����Ƥ֢��ͻ���嶵����������λ�����˽����γ�ϸ������ĩ�ֻ����Ӷ�������Ӧ�ٴ����͡�����������Ӧ��Ƥ����м��Ƥ��������ֱ����٣������쳣�����ϸ�����ӵ�Ӱ�졣
Loricrin and skin diseases
Zhang Fang*, Zhao Tian, Luo Quan, Zhang Sanquan, Zhang Xibao. *Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou 510095, China Corresponding author: Zhang Xibao, Email: zxibao@126.com ��Abstract�� Loricrin, as the major component of the cornified envelope, plays an important role in epidermal barrier function. The expression of loricrin gene is co-regulated by complex interactions between multiple transcription factors. Loricrin gene mutations can lead to loricrin keratoderma. Nuclear translocation of mutant loricrin can interfere with terminal differentiation of keratinocytes, and cause corresponding clinical phenotypes. In addition, the expression of loricrin is decreased in lesions of atopic dermatitis and psoriasis, which may be attributed to some cytokines.
���״���۲�TGM1ͻ�����Ĺ����о�